Close

Esperion Therapeutics' (ESPR) Phase 2 Trial of ETC-1002 Met Primary Endpoint in Hypercholesterolemia and Hypertension

July 28, 2015 7:32 AM EDT Send to a Friend
Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced positive top-line results from ETC-1002-014, a Phase 2 exploratory study evaluating the safety and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login